Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT

Measurable residual disease (MRD) prior to hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML) in first complete morphological remission (CR1) is an independent predictor of outcome, but few studies address CR2. This analysis by the Acute Leukemia Working Party of the European Socie...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood Cancer J
Glavni autori: Gilleece, Maria H., Shimoni, Avichai, Labopin, Myriam, Robinson, Stephen, Beelen, Dietrich, Socié, Gerard, Unal, Ali, Ganser, Arnold, Vitek, Antonin, Sengeloev, Henrik, Yakoub-Agha, Ibrahim, Tholouli, Eleni, Polge, Emmanuelle, Mohty, Mohamad, Nagler, Arnon
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2021
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8116335/
https://ncbi.nlm.nih.gov/pubmed/33980810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00479-3
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items